Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alnylam Pharmaceuticals, Inc. (ALNY) -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (165)	3/21/2025 4:10:00 PM
From: A.J. Mullen	Respond to of 166

The FDA is still working despite the firings. It approved an expansion of its approval for Amvuttra yesterday to include more patients with a genetic heart condition, ATTR. It’s marketed by Alnylam who have announced aggressive pricing. At twice the rate of existing competition. Amvuttra is injected quarterly, rather than orally daily. Alynlam claims greater compliance. It silences a gene, so it gets to the root of the cause, but the difference in effectiveness seem marginal. The big difference might lie in the payment procedure within Medicare – doctors will have an incentive to prescribe the injections. finance.yahoo.com. Alnylam is up 10%.